What Evecxia’s EVX-301 trial reveals about the future of serotonin-based psychiatry
Evecxia’s Phase 1b study uses direct brain biomarkers to validate serotonin synthesis amplification. Find out why this matters for antidepressant development.
Inside the Fresenius Kabi and Phlow Corp. epinephrine deal and why regulators will scrutinise what comes next
Fresenius Kabi and Phlow Corp. aim to onshore epinephrine production in the U.S. Find out whether this model can truly fix essential drug shortages.
FDA removes CNS limitation for Yescarta, reshaping the regulatory boundary for CAR T therapy in primary CNS lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1 […]
Genentech’s fenebrutinib challenges the PPMS treatment ceiling but does not yet reset it
Genentech has reported late-breaking Phase III data from the FENtrepid trial showing that its investigational Bruton’s tyrosine kinase inhibitor fenebrutinib achieved non-inferiority to ocrelizumab in reducing disability progression in patients with primary progressive multiple sclerosis. The results were presented at the ACTRIMS Forum 2026 and position fenebrutinib as the first oral, brain-penetrant therapy to directly […]
BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape
Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.
Why Brightseed’s glycemic control data could reshape how GLP-1 companion products are evaluated
Peer-reviewed data puts Brightseed’s BioMetaControl under the clinical microscope. Find out what this trial means for GLP-1 companions and metabolic care.
How Leyden’s CR9114 nasal spray could disrupt traditional flu vaccination models
Could a nasal spray replace flu shots? Find out how Leyden Labs’ CR9114 antibody is changing the game in influenza prevention.
Is JCR unlocking the CNS for lysosomal storage diseases before gene therapy gets there?
Find out how JCR Pharmaceuticals is redefining lysosomal disease therapy with brain-targeted delivery platforms.
WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.